Patents Assigned to GHC Research Development Corporation
  • VEGF receptor antagonists
    Patent number: 7582726
    Abstract: The present invention describes an approach to cancer therapy utilizing novel VEGF receptor antagonists. Specifically, the invention provides peptides and polynucleotides encoding VEGF receptor antagonists and methods of use thereof.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: September 1, 2009
    Assignee: GHC Research Development Corporation
    Inventors: Wen Yuan Chen, Jang P. Park
  • Acetylated therapeutic procytotoxins
    Patent number: 7550426
    Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group, and an acetyl group. These agents are useful in treating cancer, especially prostate cancer.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: June 23, 2009
    Assignee: GHC Research Development Corporation
    Inventors: Thomas E. Wagner, Xianzhong Yu
  • Lytic peptide prodrugs
    Patent number: 7456146
    Abstract: A cytotoxin can be rendered non-toxic by charge neutralizing the amino acids salient to pore assembly and/or sterically inhibiting formation of the peptide's active conformation. In the presence of specific proteases, the inactive peptide or procytotoxin can be activated to assemble into its lytic conformation and selectively destroy a target cell.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: November 25, 2008
    Assignee: GHC Research Development Corporation
    Inventors: Xianxhang Yu, Thomas E. Wagner
  • Therapeutic pore-forming peptides
    Patent number: 7425535
    Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group. These agents are useful in treating cancer, especially prostate cancer.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: September 16, 2008
    Assignee: GHC Research Development Corporation
    Inventors: Xianzhong Yu, Thomas E. Wagner
  • Human prolactin antagonist-angiogenesis inhibitor fusion proteins
    Patent number: 7339027
    Abstract: A novel fusion protein, comprising a receptor-antagonizing domain and an angiogensis inhibiting domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: March 4, 2008
    Assignee: GHC Research Development Corporation
    Inventor: Wen Y. Chen
  • Stable episomal vectors
    Patent number: 7294505
    Abstract: The present invention provides a vector system which can be stably translocated from the cytoplasm of a cell to the nucleus where it is a stable nuclear episomal vector. A basic vector system according to the present invention is generally composed of nucleic acid encoding (a) a promoter functional both in cytoplasm and nucleus, operably linked to (b) a plasmid maintenance/translocation factor and (c) an origin of replication.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: November 13, 2007
    Assignee: GHC Research Development Corporation
    Inventors: Thomas E. Wagner, Xianzhang Yu